Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen
Open accessPublished version of a preprint
The DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index.
Abstract
Vemurafenib is a BRAF kinase inhibitor (BRAFi) that is used to treat melanoma patients harboring the constitutively active BRAF-V600E mutation. However, after a few months of treatment patients often develop resistance to vemurafenib leading to disease progression. Sequence analysis of drug-resistant tumor cells and functional genomic screens has identified several genes that regulate vemurafenib resistance. Reactivation of mitogen-activated protein kinase (MAPK) pathway is a recurrent feature of cells that develop resistance to vemurafenib. We performed a genome-scale CRISPR-based knockout screen to identify modulators of vemurafenib resistance in melanoma cells with a highly improved CRISPR sgRNA library called Brunello. We identified 33 genes that regulate resistance to vemurafenib out of which 14 genes have not been reported before. Gene ontology enrichment analysis showed that the hit genes regulate histone modification, transcription and cell cycle. We discuss how inactivation of hit genes might confer resistance to vemurafenib and provide a framework for follow-up investigations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Many of the identified mediator complex components were concordantly associated with resistance to other targeted cancer therapies,44,45 but were also controversially identified as essential genes in CML cells.46”
From Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia (2024) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890 · cited 5×
“Gene Ontology (GO) term enrichment analysis was performed using DAVID [19][20].”
MethodInfluentialSzklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1131 · Cited by 17,749
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn923 · Cited by 14,108 · cited 2×
“Gene 168 Ontology (GO) term enrichment analysis was performed using DAVID [19][20].”
MethodREVIGO summarizes and visualizes long lists of gene ontology terms
Supek, F., Bošnjak, M., Škunca, N., & Šmuc, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021800 · Cited by 6,264 · cited 3×
“We removed the redundant GO terms using the online tool REVIGO [21].”
MethodInfluentialImproved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239 · cited 1×
“An improved GeCKOv2 library with minimal off-target effects and covering 19,050 human genes with 6 sgRNAs per gene (Sanjana et al. 2014) was used for a positive selection screen with vemurafenib.”
MethodGenome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234 · cited 4×
“Seminal work on the genome-wide 77 CRISPR KnockOut (GeCKO) screen [11] for regulators for vemurafenib resistance was 78 performed with two half sgRNA GeCKOv1 libraries, covering 18,000 human genes with a total 79 of 6 target sgRNAs per gene.”
BackgroundInfluentialOptimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637 · cited 4×
“(2017) used GeCKOv2 80 libraries to screen for the vemurafenib resistant A375 cells [12], [13].”
BackgroundMethodInfluentialLi, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., Irizarry, R. A., Liu, J. S., Brown, M., & Liu, X. S. (2014) · Genome Biology · doi:10.1186/s13059-014-0554-4 · Cited by 2,684 · cited 3×
“Model-based 162 Analysis of Genome-wide CRISPR/Cas9 Knockout (MAGeCK) was chosen for our analysis 163 which scores whether each gene is enriched or depleted and generates a gene ranking list [16].”
BackgroundMethodGenomic instability — an evolving hallmark of cancer
Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2858 · Cited by 2,397 · cited 1×
“Therefore, loss of HIRA and SMARCA4 is expected to cause genomic 313 instability, a hallmark of tumour cells [34].”
BackgroundLimb proportions show developmental plasticity in response to embryo movement
Pollard, A. S., Charlton, B. G., Hutchinson, J. R., Gustafsson, T., McGonnell, I. M., Timmons, J. A., & Pitsillides, A. A. (2017) · Scientific Reports · doi:10.1038/srep41926 · Cited by 2,364
Cited by
Chehelgerdi, M., Chehelgerdi, M., Khorramian-Ghahfarokhi, M., Shafieizadeh, M., Mahmoudi, E., Eskandari, F., Rashidi, M., Arshi, A., & Mokhtari-Farsani, A. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01925-5 · Cited by 251
Gene editing and its applications in biomedicine
Li, G., Li, X., Zhuang, S., Wang, L., Zhu, Y., Chen, Y., Sun, W. C., Wu, Z., Zhou, Z. L., Chen, J., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-2057-0 · Cited by 77
“CRISPR/Cas9 knockout screens are widely used and exhibit high consistency between independent screens from different laboratories with similar experimental settings (Goh et al., 2021; Shalem et al., 2014).”
BackgroundA Comprehensive Review of Various Therapeutic Strategies for the Management of Skin Cancer
Dachani, S. R., Kaleem, M., Mujtaba, M. A., Mahajan, N. M., Ali, S. A., Almutairy, A. F., Mahmood, D., Anwer, M. K., Ali, M. D., & Kumar, S. (2024) · ACS Omega · doi:10.1021/acsomega.3c09780 · Cited by 47
Schneider, L., Wies, C., Krieghoff‐Henning, E., Bucher, T.-C., Utikal, J. S., Schadendorf, D., & Brinker, T. J. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.01.021 · Cited by 33
The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
Paris, A., Tardif, N., Baietti, F. M., Berra, C., Leclair, H. M., Leucci, E., Galibert, M., & Corre, S. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215677 · Cited by 26
Metadata
- Authors
- Goh, C. J. H., Wong, J. H., El Farran, C., Tan, B. X., Coffill, C. R., Loh, Y.-H., Lane, D., & Arumugam, P.
- Affiliations
- Agency for Science, Technology and Research (SG)
- Epigenetics and Cell Fates Laboratory, A*STAR Institute of Molecular and Cell Biology, Singapore 138673, Singapore
- Corresponding author
- Arumugam, Prakash
- Venue
- G3 Genes|Genomes|Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-01-11
- Volume
- 11
- Issue
- 2
- ISSN
- 2160-1836 (ISSN-L)
- PMC
- PMC8022920
- OpenAlex
- W3129457230
- Cited by
- 20
- References
- 76
- Citations by year
- 2026: 7 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 1
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- G3 Genes Genomes Genetics (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Agency for Science, Technology and Research (A*STAR)
- Industry Alignment Fund—Pre-Positioning Programme (H18/01/a0/B14)
- A*STAR Innovations in Food and Chemical Safety
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- vemurafenib resistance, melanoma, BRAF V600E mutation, BRAF inhibitors, MAPK pathway reactivation, histone modifications, transcriptional regulation, cell cycle genes, drug resistance genes
- MeSH terms
- Vemurafenib, Humans, Melanoma, Mutation, Drug Resistance, Neoplasm, Cell Line, Tumor, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen. https://app.cochat.ai/papers/10.1093/g3journal/jkaa069
- The paper
- Goh, C. J. H., Wong, J. H., El Farran, C., Tan, B. X., Coffill, C. R., Loh, Y.-H., Lane, D., & Arumugam, P. (2021). Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen. G3 Genes|Genomes|Genetics. https://doi.org/10.1093/g3journal/jkaa069
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.